Tumor Cell Expression of CD163 is Associated to Postoperative Radiotherapy and Poor Prognosis in Patients with Breast Cancer Treated with Breast-conserving Surgery

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2018 May 5

PMID 29725763

Citations 29

Authors

Stina Garvin

Husam Oda

Lars-Gunnar Arnesson

Annelie Lindstrom

Ivan Shabo

Affiliations

Soon will be listed here.

Abstract

Purpose: Cancer cell fusion with macrophages results in highly tumorigenic hybrids that acquire genetic and phenotypic characteristics from both maternal cells. Macrophage traits, exemplified by CD163 expression, in tumor cells are associated with advanced stages and poor prognosis in breast cancer (BC). In vitro data suggest that cancer cells expressing CD163 acquire radioresistance.

Methods: Tissue microarray was constructed from primary BC obtained from 83 patients treated with breast-conserving surgery, 50% having received postoperative radiotherapy (RT) and none of the patients had lymph node or distant metastasis. Immunostaining of CD163 in cancer cells and macrophage infiltration (MI) in tumor stroma were evaluated. Macrophage:MCF-7 hybrids were generated by spontaneous in vitro cell fusion. After irradiation (0, 2.5 and 5 Gy γ-radiation), both hybrids and their maternal MCF-7 cells were examined by clonogenic survival.

Results: CD163-expression by cancer cells was significantly associated with MI and clinicopathological data. Patients with CD163-positive tumors had significantly shorter disease-free survival (DFS) after RT. In vitro generated macrophage:MCF-7 hybrids developed radioresistance and exhibited better survival and colony forming ability after radiation compared to maternal MCF-7 cancer cells.

Conclusions: Our results suggest that macrophage phenotype in tumor cells results in radioresistance in breast cancer and shorter DFS after radiotherapy.

Citing Articles

Exploring the Prognostic Role of Trop-2, CD47, and CD163 Expression Levels on Survival Outcomes in Patients with Triple-Negative Breast Cancer.

Yuceer R, Aydin S, Gelir I, Koc T, Tuncer E, Ucar M Diagnostics (Basel). 2025; 15(2).

PMID: 39857116 PMC: 11764053. DOI: 10.3390/diagnostics15020232.

Research progress on factors affecting the sensitivity of breast cancer to radiotherapy: a narrative review.

Zhang Q, Qian F, Cai M, Liu R, Chen M, Li Z Transl Cancer Res. 2024; 13(7):3869-3888.

PMID: 39145054 PMC: 11319974. DOI: 10.21037/tcr-24-71.

Predictive and Prognostic Relevance of Tumor-Infiltrating Immune Cells: Tailoring Personalized Treatments against Different Cancer Types.

Dakal T, George N, Xu C, Suravajhala P, Kumar A Cancers (Basel). 2024; 16(9).

PMID: 38730579 PMC: 11082991. DOI: 10.3390/cancers16091626.

A2AR Expression and Immunosuppressive Environment Independent of and Mutations in Pseudomyxoma Peritonei.

Kusamura S, Busico A, Conca E, Capone I, Agnelli L, Lorenzini D Biomedicines. 2023; 11(7).

PMID: 37509688 PMC: 10377259. DOI: 10.3390/biomedicines11072049.

The Significance of SPP1 in Lung Cancers and Its Impact as a Marker for Protumor Tumor-Associated Macrophages.

Matsubara E, Yano H, Pan C, Komohara Y, Fujiwara Y, Zhao S Cancers (Basel). 2023; 15(8).

PMID: 37190178 PMC: 10136569. DOI: 10.3390/cancers15082250.

References

Shabo I, Midtbo K, Andersson H, Akerlund E, Olsson H, Wegman P . Macrophage traits in cancer cells are induced by macrophage-cancer cell fusion and cannot be explained by cellular interaction. BMC Cancer. 2015; 15:922. PMC: 4653907. DOI: 10.1186/s12885-015-1935-0. View

Lindstrom A, Midtbo K, Arnesson L, Garvin S, Shabo I . Fusion between M2-macrophages and cancer cells results in a subpopulation of radioresistant cells with enhanced DNA-repair capacity. Oncotarget. 2017; 8(31):51370-51386. PMC: 5584255. DOI: 10.18632/oncotarget.17986. View

Bastida-Ruiz D, Van Hoesen K, Cohen M . The Dark Side of Cell Fusion. Int J Mol Sci. 2016; 17(5). PMC: 4881464. DOI: 10.3390/ijms17050638. View

Biswas S, Mantovani A . Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010; 11(10):889-96. DOI: 10.1038/ni.1937. View

Wang R, Sun X, Wang C, Hu P, Chu C, Liu S . Spontaneous cancer-stromal cell fusion as a mechanism of prostate cancer androgen-independent progression. PLoS One. 2012; 7(8):e42653. PMC: 3411834. DOI: 10.1371/journal.pone.0042653. View

Ohkuri T, Kosaka A, Ishibashi K, Kumai T, Hirata Y, Ohara K . Intratumoral administration of cGAMP transiently accumulates potent macrophages for anti-tumor immunity at a mouse tumor site. Cancer Immunol Immunother. 2017; 66(6):705-716. PMC: 11028681. DOI: 10.1007/s00262-017-1975-1. View

Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans V . Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 366(9503):2087-106. DOI: 10.1016/S0140-6736(05)67887-7. View

Gonzalez-Angulo A, Morales-Vasquez F, Hortobagyi G . Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol. 2007; 608:1-22. DOI: 10.1007/978-0-387-74039-3_1. View

Powell A, Anderson E, Davies P, Silk A, Pelz C, Impey S . Fusion between Intestinal epithelial cells and macrophages in a cancer context results in nuclear reprogramming. Cancer Res. 2011; 71(4):1497-505. PMC: 3079548. DOI: 10.1158/0008-5472.CAN-10-3223. View

10.

Georgoudaki A, Prokopec K, Boura V, Hellqvist E, Sohn S, Ostling J . Reprogramming Tumor-Associated Macrophages by Antibody Targeting Inhibits Cancer Progression and Metastasis. Cell Rep. 2016; 15(9):2000-11. DOI: 10.1016/j.celrep.2016.04.084. View

11.

Wei H, Nickoloff J, Chen W, Liu H, Lo W, Chang Y . FOXF1 mediates mesenchymal stem cell fusion-induced reprogramming of lung cancer cells. Oncotarget. 2014; 5(19):9514-29. PMC: 4253450. DOI: 10.18632/oncotarget.2413. View

12.

Shabo I, Olsson H, Sun X, Svanvik J . Expression of the macrophage antigen CD163 in rectal cancer cells is associated with early local recurrence and reduced survival time. Int J Cancer. 2009; 125(8):1826-31. DOI: 10.1002/ijc.24506. View

13.

Komohara Y, Fujiwara Y, Ohnishi K, Takeya M . Tumor-associated macrophages: Potential therapeutic targets for anti-cancer therapy. Adv Drug Deliv Rev. 2015; 99(Pt B):180-185. DOI: 10.1016/j.addr.2015.11.009. View

14.

Franken N, Rodermond H, Stap J, Haveman J, van Bree C . Clonogenic assay of cells in vitro. Nat Protoc. 2007; 1(5):2315-9. DOI: 10.1038/nprot.2006.339. View

15.

Nagler C, Hardt C, Zanker K, Dittmar T . Co-cultivation of murine BMDCs with 67NR mouse mammary carcinoma cells give rise to highly drug resistant cells. Cancer Cell Int. 2011; 11(1):21. PMC: 3135493. DOI: 10.1186/1475-2867-11-21. View

16.

Maier P, Hartmann L, Wenz F, Herskind C . Cellular Pathways in Response to Ionizing Radiation and Their Targetability for Tumor Radiosensitization. Int J Mol Sci. 2016; 17(1). PMC: 4730344. DOI: 10.3390/ijms17010102. View

17.

Johansson C, Youssef S, Koleckar K, Holbrook C, Doyonnas R, Corbel S . Extensive fusion of haematopoietic cells with Purkinje neurons in response to chronic inflammation. Nat Cell Biol. 2008; 10(5):575-83. PMC: 4230437. DOI: 10.1038/ncb1720. View

18.

Leek R, Lewis C, Whitehouse R, Greenall M, Clarke J, Harris A . Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res. 1996; 56(20):4625-9. View

19.

Maniecki M, Etzerodt A, Ulhoi B, Steiniche T, Borre M, Dyrskjot L . Tumor-promoting macrophages induce the expression of the macrophage-specific receptor CD163 in malignant cells. Int J Cancer. 2012; 131(10):2320-31. DOI: 10.1002/ijc.27506. View

20.

Golan T, Milella M, Ackerstein A, Berger R . The changing face of clinical trials in the personalized medicine and immuno-oncology era: report from the international congress on clinical trials in Oncology & Hemato-Oncology (ICTO 2017). J Exp Clin Cancer Res. 2017; 36(1):192. PMC: 5745625. DOI: 10.1186/s13046-017-0668-0. View